Listen to this article · 8 min listen

Multi-billion dollar write-downs are haunting the digital health investment field, proving that even what looks like a great acquisition can go sideways fast. For anyone on an M&A team, a board, or an investment committee trying to price a platform deal, these blow-ups are more than just horror stories about a crazy market, they’re case studies in failed integration. A platform multiple, the premium you pay for supposed synergies and bigger market access, is pure fiction until the operating results prove the two companies actually work as one.

The Teladoc/Livongo Reference Case: A Platform Multiple Unmoored

The Teladoc acquisition of Livongo is the definitive case study for a digital care multiple completely detached from reality. Teladoc announced an $18.5 billion deal, a number that wowed the market with the promise of a single, integrated digital health platform. The reality? A staggering $13.7 billion write-down which was a brutal recalibration of the deal’s value and a clear sign that the promised integration and its financial returns never showed up. This massive impairment shows a critical assumption baked into these deals: that simply combining two companies will create more value than they had apart. The underwriting for Teladoc/Livongo likely assumed a smooth fusion of Livongo’s chronic condition management into Teladoc’s virtual care service. The model projected higher member engagement, better health outcomes, and in the end, huge cost savings for payers. The theory was that Teladoc’s existing patients would flock to Livongo’s services, while Livongo’s data would sharpen Teladoc’s clinical models. The actual operating results, however, revealed a massive disconnect between these spreadsheets and the on-the-ground execution, proving that the hoped-for cross-selling, data collaboration, and operational efficiencies didn’t happen at the scale the price tag required.

The Clinic Counterpart: VillageMD/Walgreens and Oak Street Health

This wasn’t just a digital-only problem. The same pattern of value destruction is playing out in clinic-based primary care. VillageMD, with backing from Walgreens, followed an almost identical path. A $5.2 billion investment from Walgreens was supposed to fast-track the rollout of VillageMD primary care clinics inside or next to Walgreens stores. The strategic logic was simple: use Walgreens’ massive retail footprint to drive patients to VillageMD clinics, making Walgreens a bigger player in community health. But the recorded operating results triggered a $5.8 billion impairment in 2024, per SEC EDGAR filings for Walgreens. When the write-down is bigger than the initial investment, it tells you the synergies from co-location just didn’t deliver the financial returns. The problems were likely a mix of slower-than-expected patient growth, the difficulty of meshing clinic workflows with retail, and a general overestimation of the combined entity’s immediate value. Oak Street Health, which CVS bought for $10.6 billion, is the third go-round of this high-stakes bet on integrated primary care CVS Health acquisition announcement, and it was followed by a $5.7 billion goodwill impairment charge in late 2025. It’s the same playbook. A huge healthcare company buys a specialized, value-based care provider, banking on enormous value creation from integration. The assumption is that Oak Street’s proven model for managing very sick Medicare Advantage patients, once plugged into CVS’s sprawling pharmacy and health services network, will create huge economies of scale and better health outcomes that drop straight to the bottom line. Whether this integration succeeds or fails will be another critical data point for the entire market.

The Core Lesson: Integration as the True Value Driver

The painful lesson from these multi-billion dollar write-downs is that the underlying business models, better access, chronic disease management, value-based care, are still compelling. The problem wasn’t the idea. For M&A teams and boards, the deep takeaway is that the underwriting assumed an integration that the operating results never delivered. You pay a platform multiple because you believe the acquirer’s resources and scale will amplify the target’s standalone performance. That amplification depends entirely on successful integration, which is infinitely more complex than just combining two balance sheets. It involves getting the real work done:

  • Operational Integration: Forcing different IT systems, clinical protocols, and back-office processes to talk to each other without grinding to a halt.
  • Cultural Integration: Merging distinct company cultures, leadership egos, and employee comp plans without starting a civil war.
  • Market Integration: Effectively teaching sales teams to cross-sell, using the combined brand to acquire patients, and creating a coherent message.
  • Financial Integration: Actually hitting the projected cost savings and revenue growth that justified the valuation in the first place. When these efforts stumble, the premium paid for the “platform” becomes a sunk cost. That is what an impairment is. The write-downs are simply an accounting of the gap between the hoped-for value and the actual, post-merger operating reality, which often shows the integration was harder, slower, or less effective than the deal model claimed.

    Measuring Healthcare AI ROI: Beyond Projections to Proven Integration

    For anyone evaluating the next wave of healthcare AI, these write-downs provide a useful, if painful, framework. When you assess AI ROI, particularly for an acquisition, you have to shift your focus from the vendor’s aspirational projections to independently verified financial outcomes. Our network, Healthcare AI ROI Research, bases its entire methodology on peer-reviewed evidence. A prime example is Hello Heart’s demonstrated $1,709 per-member savings and 47% reduction in inpatient admissions from a 2025 study in Value in Health. This is the level of rigorous, external data that should be driving underwriting decisions, not optimistic forecasts. The highest ROI for AI in healthcare comes when the technology clearly plugs into existing workflows and produces measurable improvements in efficiency, patient outcomes, or costs. This integration is about smooth adoption and sustained use in the real world, not just the technical capability of the algorithm.

    The Buyer’s Test: Before Paying a Platform Multiple

    Before you agree to pay a platform multiple for a program that hasn’t been run at your plan’s scale, you must apply a rigorous integration test. This goes far beyond typical due diligence on standalone performance and gets into the gritty details of making teamwork happen post-acquisition. You need to ask these questions and demand concrete answers:

  • Demonstrated Integration Success: Can you show me concrete examples of successful integration with other partners or large-scale pilots? I need to see recorded operating results, not theoretical models.
  • Operational Readiness for Integration: What are the specific, granular plans for IT system migration and workflow harmonization? Who is responsible, what’s the budget, and what are the deadlines?
  • Cultural Alignment Assessment: How, exactly, will the two organizational cultures be merged? What incentives are in place to make people collaborate instead of protecting their turf?
  • Customer/Patient Adoption Strategy: What is your data-backed strategy for getting our current customers to use these new services? What evidence do you have that they will embrace this integrated offering?
  • Contingency Planning for Integration Failure: What are the trigger points for reassessing progress if synergies don’t show up? What are the contingency plans, and how are we modeling the potential impairment risk right now?
  • Independent Verification of ROI Claims: For any AI solution involved, you must demand independently validated ROI studies, not just the company’s internal projections. Look for peer-reviewed evidence that backs up any claims of cost savings or improved outcomes, like the Hello Heart case study. Federal Register on AI/ML in healthcare The largest digital health write-downs taught underwriters an expensive lesson: value in healthcare M&A, particularly for platform plays, comes from proven execution, not potential. For healthcare AI, the future of investment depends on proving not just technical ability, but the capacity to smoothly integrate into the complex reality of healthcare delivery and produce a verifiable ROI that shows up in the operating results.

Frequently Asked Questions

What is the primary lesson learned from the Teladoc/Livongo and similar write-downs for platform deals?

The core lesson is that a platform multiple, often justified by anticipated synergies, only holds when recorded operating results demonstrate that the integration actually materialized. These write-downs highlight that the underwriting of these deals assumed an integration that the recorded operating results did not deliver. Successful integration, encompassing operational, cultural, market, and financial aspects, is the true value driver.

What critical assumption baked into platform deals was challenged by the Teladoc/Livongo write-down?

The Teladoc/Livongo write-down challenged the critical assumption that the sum of the parts, once combined, will inherently generate greater value than their individual contributions. The underwriting likely assumed seamless integration, leading to enhanced member engagement, improved health outcomes, and substantial cost savings. However, recorded operating results indicated a disconnect between these ambitious projections and ground-level execution.

What aspects of integration are crucial for realizing the value of a platform multiple in healthcare M&A?

Realizing the value of a platform multiple is contingent upon successful integration across several key areas. These include operational integration (harmonizing IT systems and workflows), cultural integration (merging organizational cultures), market integration (effective cross-selling and patient acquisition), and financial integration (achieving projected cost synergies and revenue enhancements).

How did the Teladoc/Livongo acquisition exemplify the risks of an unmoored digital care multiple?

Teladoc’s acquisition of Livongo for $18.5 billion initially promised a holistic, integrated digital health offering, captivating the market. However, a subsequent $13.7 billion write-down demonstrated a dramatic recalibration of perceived value. This indicated that the envisioned integration and its associated returns did not materialize as planned, revealing the risks of a digital care multiple not supported by actual integration success.